Adbry, Adtralza(tralokinumab)
Adbry, Adtralza (tralokinumab) is an antibody pharmaceutical. Tralokinumab was first approved as Adtralza on 2021-06-17. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Adbry
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tralokinumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Adbry | tralokinumab-ldrm | LEO Pharma | N-761180 RX | 2021-12-27 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adbry | Biologic Licensing Application | 2024-05-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 2 | 10 | 1 | 3 | 17 |
| Eczema | D004485 | — | L30.9 | 1 | 2 | 10 | 1 | 3 | 17 |
| Dermatitis | D003872 | — | L30.9 | 1 | 2 | 10 | 1 | 3 | 17 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tralokinumab |
| INN | tralokinumab |
| Description | Tralokinumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 5L6Y |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743081 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12169 |
| UNII ID | GK1LYB375A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Tralokinumab – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,276 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,952 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use